HMDCF (HUTCHMED (China)) Intrinsic Value: Projected FCF: $-0.36 (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HMDCF HUTCHMED (China) Ltd HMDCF
69 GF Score
Price $2.16
GF Value $2.30
! 8 Warning Signs
View Full Analysis

What is HUTCHMED (China) Intrinsic Value: Projected FCF?

HUTCHMED (China) HMDCF 69 Intrinsic Value: Projected FCF is $-0.36 as of Aug. 09, 2026. GuruFocus rates HMDCF with a GF Score™ of 69/100 and a GF Value™ of $2.30. The stock has 8 warning signs investors should review. Among 540 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 185185% on this metric.

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2026-08-09), HUTCHMED (China)'s Intrinsic Value: Projected FCF is $-0.36. The stock price of HUTCHMED (China) is $2.16. Therefore, HUTCHMED (China)'s Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for HUTCHMED (China)'s Intrinsic Value: Projected FCF or its related term are showing as below:

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of HUTCHMED (China) was 115.00. The lowest was 5.13. And the median was 23.88.

HMDCF's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.565
* Ranked among companies with meaningful Price-to-Projected-FCF only.

HUTCHMED (China)  (OTCPK:HMDCF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

HUTCHMED (China)'s Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.16/-0.34115863328883
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HUTCHMED (China) Intrinsic Value: Projected FCF Related Terms


HUTCHMED (China) Intrinsic Value: Projected FCF Historical Data

* Premium members only.

The historical data trend for HUTCHMED (China)'s Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HUTCHMED (China) Intrinsic Value: Projected FCF Chart

HUTCHMED (China) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 -0.56 -0.65 -0.72 -0.55

HUTCHMED (China) Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.72 0.00 -0.55 0.00

HMDCF vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HUTCHMED (China) Price-to-Projected-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s Price-to-Projected-FCF falls into.


HMDCF
69GF Score
HUTCHMED (China) Ltd HMDCF
Intrinsic Value: Projected FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HUTCHMED (China) Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get HUTCHMED (China)'s Free Cash Flow(6 year avg) = $-88.47.

HUTCHMED (China)'s Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec25)*0.8)/Shares Outstanding (Diluted Average)
=(14.560228559972*-88.469428571429+1237.926*0.8)/872.891
=-0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Intrinsic Value: Projected FCF of $-0.36 mean?
HUTCHMED (China) (HMDCF) has a Intrinsic Value: Projected FCF of $-0.36 as of Aug. 09, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on HUTCHMED (China) and its competitors. Over the past decade, HUTCHMED (China)'s Intrinsic Value: Projected FCF has ranged from 5.13 to 115.00. According to the industry distribution chart, HUTCHMED (China) ranks #999999 out of 540 companies in the Drug Manufacturers industry.
Is HUTCHMED (China)'s Intrinsic Value: Projected FCF too high?
HUTCHMED (China)'s current Intrinsic Value: Projected FCF is $-0.36. Over the past 10 years, this metric has ranged from a low of 5.13 to a high of 115.00. Based on the distribution chart, HUTCHMED (China) ranks #999999 out of 540 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #999999 out of 540 companies for Intrinsic Value: Projected FCF. This places HUTCHMED (China) in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.57. Historically, HUTCHMED (China)'s own Intrinsic Value: Projected FCF has ranged from 5.13 to 115.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.57, based on 540 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Intrinsic Value: Projected FCF is $-0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
HUTCHMED (China) (HMDCF) has a current Intrinsic Value: Projected FCF of $-0.36. The stock's GF Value™ is $2.30, compared to a current price of $2.16 — trading 6.1% below its estimated fair value. The current Intrinsic Value: Projected FCF is $-0.36. HUTCHMED (China)'s overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current Intrinsic Value: Projected FCF is $-0.36 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HUTCHMED (China) (HMDCF) Overvalued in 2026?

Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued. The current stock price of $2.16 is trading 6.1% below its estimated GF Value™ of $2.30.

Key valuation signals for HMDCF:

  • Intrinsic Value: Projected FCF: $-0.36
  • GF Value™: $2.30 vs. price of $2.16 (6.1% below fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HUTCHMED (China) Business Description

Address 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
69GF Score

Get the complete analysis for HMDCF

Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price
$2.30
GF Value